Encellin has developed an Encapsulated Cell Replacement Therapy (EnCRT) to isolate therapeutic cells from the body's immune system, to help therapeutic cells survive in the body. Once implanted, cells within the porous EnCRT are able to exchange the biomolecules with the body, which Encellin seeks to demonstrate will provide a therapeutic benefit and function as a living medicine.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 12/13/23 | $9,900,000 |
Khosla Ventures Y Combinator | undisclosed |
